School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
School of Basic Medicine Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Phytomedicine. 2023 Jul;115:154845. doi: 10.1016/j.phymed.2023.154845. Epub 2023 Apr 28.
As a common cerebrovascular disease (CVD) of the elderly, ischemic stroke (IS) is characterized by high disability and mortality. Excessive autophagy induced by IS is implicated in neuronal death, therefore, the inhibition of immoderate autophagy is viewed as a potential therapeutic avenue to treat IS. Calysoin (CA) is a bioactive component of Radix Astragali, which has been widely used to treat CVDs. However, the mechanism of the treatment of IS by CA is still problematic.
Based on the result of network pharmacology, whether CA inhibited autophagy by regulating the STAT3/FOXO3a pathway to alleviate cerebral ischemia-reperfusion injury (CIRI) was investigated in vivo and in vitro for the first time.
Integrate computational prediction and experimental validation based on network pharmacology.
In current study, network pharmacology was applied to predict the mechanism of the treatment of IS by CA, and it was shown that CA alleviated CIRI by inhibiting autophagy via STAT3/FOXO3a signaling pathway. One hundred and twenty adult male specific pathogen-free Sprague-Dawley rats in vivo and PC12 cells in vitro were used to verify the above prediction results. The rat middle cerebral artery occlusion/reperfusion (MCAO/R) model was established by suture method, and oxygen glucose deprivation/re-oxygenation (OGD/R) model was used to simulate cerebral ischemia in vivo. The content of MDA, TNF-α, ROS and TGF-β1 in rat serum were detected by ELISA kits. The mRNA and protein expressions in brain tissue were detected by RT-PCR and Western Blotting. The expressions of LC3 in brain were detected immunofluorescent staining.
The experimental results demonstrated that administration of CA dosage-dependently improved rat CIRI as evidenced by the reduction in the cerebral infarct volume, amelioration of the neurological deficits. HE staining and transmission electron microscopy results revealed that CA ameliorated cerebral histopathological damage, abnormal mitochondrial morphology, and damaged mitochondrial cristae structure in MCAO/R rats. CA treatment exerted protective effects in CIRI by inhibiting inflammation response, oxidative stress injury, and cell apoptosis in rat and PC12 cells. CA relieved excessive autophagy induced by MCAO/R or OGD/R through downregulating the LC3Ⅱ/LC3Ⅰ ratio and upregulating the SQSTM1 expression. CA treatment also decreased p-STAT3/STAT3 and p-FOXO3a/FOXO3a ratio in the cytoplasm and modulated the autophagy-related gene expression both in vivo and in vitro.
Treatment with CA attenuated CIRI by reducing excessive autophagy via STAT3/FOXO3a signal pathway in rat and PC12 cells.
作为一种常见的老年脑血管疾病(CVD),缺血性脑卒中(IS)的特点是高残疾率和高死亡率。IS 引起的过度自噬与神经元死亡有关,因此,抑制过度自噬被视为治疗 IS 的潜在治疗途径。毛蕊异黄酮(CA)是黄芪的一种生物活性成分,已广泛用于治疗 CVD。然而,CA 治疗 IS 的机制仍然存在问题。
基于网络药理学的研究结果,首次在体内和体外研究 CA 是否通过调节 STAT3/FOXO3a 通路抑制自噬来减轻脑缺血再灌注损伤(CIRI)。
整合基于网络药理学的计算预测和实验验证。
在本研究中,应用网络药理学预测 CA 治疗 IS 的机制,并表明 CA 通过 STAT3/FOXO3a 信号通路抑制自噬来减轻 CIRI。体内采用 120 只成年雄性无特定病原体 Sprague-Dawley 大鼠,体外采用 PC12 细胞验证上述预测结果。采用缝线法建立大鼠大脑中动脉闭塞/再灌注(MCAO/R)模型,采用氧葡萄糖剥夺/再氧合(OGD/R)模型模拟体内脑缺血。通过 ELISA 试剂盒检测大鼠血清中 MDA、TNF-α、ROS 和 TGF-β1 的含量。通过 RT-PCR 和 Western Blotting 检测脑组织中 mRNA 和蛋白的表达。通过免疫荧光染色检测脑内 LC3 的表达。
实验结果表明,CA 呈剂量依赖性地改善大鼠 CIRI,表现为脑梗死体积减小,神经功能缺损改善。HE 染色和透射电镜结果显示,CA 改善了 MCAO/R 大鼠的脑组织病理学损伤、异常线粒体形态和受损的线粒体嵴结构。CA 通过抑制炎症反应、氧化应激损伤和细胞凋亡,在大鼠和 PC12 细胞中发挥对 CIRI 的保护作用。CA 通过下调 LC3Ⅱ/LC3Ⅰ比值和上调 SQSTM1 表达,减轻 MCAO/R 或 OGD/R 诱导的过度自噬。CA 还降低了细胞质中 p-STAT3/STAT3 和 p-FOXO3a/FOXO3a 比值,并在体内和体外调节自噬相关基因的表达。
CA 通过降低 STAT3/FOXO3a 信号通路介导的自噬来减轻大鼠和 PC12 细胞中的 CIRI。